ClinicalTrials.gov
ClinicalTrials.gov Menu

Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03356769
Recruitment Status : Recruiting
First Posted : November 29, 2017
Last Update Posted : November 29, 2017
Sponsor:
Collaborator:
Shijiazhuang Pharmaceutical Group Co. Ltd.
Information provided by (Responsible Party):
Peking Union Medical College Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : November 20, 2019
  Estimated Study Completion Date : November 20, 2020
Publications: